Page 93 - Priority Review News Today

(RTTNews) - Seagen Inc. (SGEN) said FDA has accepted for Priority Review the supplemental New Drug Application seeking accelerated approval for TU...

SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegener

Approvals in psoriasis, hepatorenal syndrome, and neutropenia; novel therapy gains Priority Review for Rett Syndrome; and the effects of multivitamin supplementation assessed in cognitive function.  

Cancer-focused biotech Tracon Pharmaceuticals (TCON) announced Wednesday that the FDA granted fast-track designation for envafolimab (KN035) as a treatment for patients with...

The FDA has accepted for Priority Review the Biologics License Application (BLA) for velmanase alfa for the treatment of alpha-mannosidosis.

Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field

Press release content from Business Wire. The AP news staff was not involved in its creation.

Dupixent (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis Nearly three times as many Dupixent patients experienced

Investegate announcements from Sanofi - Aventis Groupe, Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials...